Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis by Leung, Ying Ying et al.
        
Citation for published version:
Leung, YY, Orbai, AM, Ogdie, A, Hojgaard, P, Holland, R, Goel, N, Chau, J, Coates, LC, Strand, V, Gladman,
DD, Mease, PJ, Christensen, R & Tillett, W 2021, 'Appraisal of candidate instruments for assessment of the









This is the author accepted manuscript of an article published in final form in Leung, YY, Orbai, AM, Ogdie, A,
Hojgaard, P, Holland, R, Goel, N, Chau, J, Coates, LC, Strand, V, Gladman, DD, Mease, PJ, Christensen, R &
Tillett, W 2021, 'Appraisal of candidate instruments for assessment of the physical function domain in patients




If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.





Appraisal of candidate instruments for assessment of the physical function domain in 
patients with psoriatic arthritis  
Ying Ying Leung1, Ana-Maria Orbai2, Alexis Ogdie3, Pil Hojgaard4, Richard Holland5, Niti 
Goel6, Jeffrey Chau7, Laura C Coates8, Vibeke Strand9, Dafna D Gladman10, Philip Mease11, 
Robin Christensen4, 12, William Tillett13 
1. Singapore General Hospital, Duke-NUS Medical School, Singapore 
2. Director Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins 
University School of Medicine, Baltimore, Maryland, USA 
3. Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, 
Philadelphia, Pennsylvania, USA 
4. Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg 
Hospital, Denmark 
5. Concord Repatriation General Hospital, Sydney, Australia 
6. Patient Research Partner, Adjunct Assistant Professor, Duke University School of 
Medicine, Durham, North Carolina, USA 
7. Patient Research Partner, Hong Kong Psoriatic Arthritis Association, Hong Kong, China 
8. National Institute for Health Research Clinician Scientist, Nuffield Department of 
Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, 
Oxford, United Kingdom 
9. Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo 
Alto, California, USA 
10. Division of Rheumatology, University of Toronto, Senior Scientist, Krembil Research 
Institute, Director, Psoriatic Arthritis Program, University Health Network, Toronto 
Western Hospital, Toronto, Ontario, Canada 
11. Swedish Medical Center/Providence St Joseph Health and University of Washington 
School of Medicine, Seattle, Washington, USA 
12. Research Unit of Rheumatology, Department of Clinical Research, University of 
Southern Denmark, Odense University Hospital, Denmark. 
13. Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, United 
Kingdom 
 
Correspondence to: Ying-Ying Leung, MD; Department of Rheumatology and Immunology, 
Singapore General Hospital, The Academia, level 4, 20 College Road, Singapore 169856, 







Objective. Numerous Patient-Reported Outcome Measures (PROMs) exist for the 
measurement of physical function for psoriatic arthritis (PsA), but only a few are validated. 
The objective of this project was to prioritize PROMs for measuring physical function for 
potential incorporation into a standardized Outcome Measurement Set for PsA  
Methods. A working group of 13 members including two patient research partners was 
formed. We applied a template to assess and prioritize evaluation of PROMs for physical 
function, through their identification, discussions and Delphi exercises to achieve consensus. 
Results. PROMs measuring physical function in PsA were identified through a systematic 
literature review and recommendations by the working group. The rationale for inclusion and 
exclusion from the original list of existing PROMs was thoroughly discussed and two rounds 
of Delphi exercises were conducted to achieve consensus. Six PROMs were prioritized: 
Health Assessment Questionnaire and four modifications (HAQ-Disability Index, HAQ-
Spine, modified HAQ, Multidimensional HAQ), Medical Outcome Survey Short Form-36 
(SF-36)-physical functioning domain and the PROMIS physical functioning module.  
Conclusion. We prioritized six physical function PROMs for PsA. These six PROMs will 
undergo further appraisal using the Outcome Measures in Rheumatology (OMERACT) Filter 
2.1. 
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Psoriatic arthritis (PsA) is a  chronic inflammatory disease with manifestations  
including arthritis, enthesitis, dactylitis, spondylitis, skin and nail psoriasis (1, 2). PsA causes 
damage of articular joints and can profoundly impact physical function and health-related 
quality of life (HRQoL) in affected individuals. The Group for Research and Assessment of 
Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology 
(OMERACT) are working to combine perspectives of care providers, researchers and patient 
research partners (PRPs) to update the PsA Core Outcome Set which identifies the key 
outcomes to be measured in randomized controlled trials (RCTs) and longitudinal 
observational studies (LOS) (3). Core Outcome Sets represent the minimum domains that 
should be measured and reported in all RCTs and LOS of a specific condition (4). Use of 
Core Outcome Sets does not imply that outcomes in a particular RCT should be restricted to 
those endpoints.  OMERACT advocates that each trial should measure the Core Outcome Set 
which is based on both a Core Domain Set (the What to measure) and a Core Outcome 
Measurement Set (the How to measure) (5). A Core Domain Set for PsA was updated and 
endorsed in 2016 (3).   
The lack of standardization of outcome measurement instruments in PsA RCTs and 
LOS has been highlighted, resulting in inconsistency of data reporting and heterogeneity in 
results (6). After finalizing the Core Domain Set, the GRAPPA-OMERACT PsA Core 
Outcome Set working group is currently leading the effort to develop and ratify a 
standardized Core Outcome Measurement Set (7). The process to do so follows 
recommendations outlined in the OMERACT (Outcome Measurement in Rheumatology) 
Filter 2.1 (5, 8). The OMERACT Filter 2.1 is a set of standards for evidence-based decision 





instrument to assess a certain domain using the OMERACT Filter 2.1 involves multiple work 
streams including systematic literature reviews (SLR), with appraisal and synthesis of the 
evidence on instrument properties; discussions among stakeholders, and Delphi consensus 
exercises. The synthesis of evidence follows the pillars of OMERACT Filter 2.1: Domain 
match (instrument measuring what it is supposed to measure), Feasibility (instrument is 
practical to use), Truth (degree to which the instrument’s score make numerical sense) and 
Discrimination (instrument can distinguish situation of no change versus change, is sensitive 
to change in RCTs, and has a threshold of meaning for interpretation) (5). 
Physical function is included in the PsA Core Domain Set as it has been identified as 
one of the core  domains reflecting disease impact in PsA patients (9-11). Several instruments 
are available to measure physical function in PsA, including those originally developed for 
use in other conditions, such as rheumatoid arthritis (RA), as well as newer instruments 
developed specifically for PsA (12).  The process to prioritize instruments prior to appraisal 
using the OMERACT Filter 2.1 is conducted by individual working groups.  The PsA Core 
Outcome Set working group steering committee developed a template to facilitate this 
process, and this template has been described elsewhere (13). It includes the formation of a 
working group, identification of instruments and preliminary appraisal of existing evidence, 
and discussions and Delphi exercises to prioritize instruments that have the highest potential 
to fulfill OMERACT Filter 2.1. This report details the steps taken by the physical function 
working group to prioritize patient-reported outcome measures (PROMs) for the assessment 








This report describes application of a template to the physical function domain for 
PsA to prioritize instruments to undergo the OMERACT Filter 2.1.  
1. Formation of a working group for the outcome domain.  
The working group members were identified through GRAPPA, and included 
personnel with expertise in the physical function domain in PsA. Candidates were invited 
from within the steering committee and recommendation from working group members. The 
working group involved at least 2 Patient Research Partners (PRPs) who were invited to 
participate by the GRAPPA PRP Chair.   
2. Identification and preliminary appraisal of measurement instruments for the domain. 
We identified instruments for measuring physical function based on results from a 
recent systematic review of measurement properties of PROMs in PsA that involved both 
health professionals and PRPs (14). In the previous work, published articles with data 
regarding development or assessment of the measurement properties of PROMs were 
identified (14);  these measurement properties were evaluated using the approach described 
by Prinsen et al (15) and the COnsensus-based Standards for the selection of health 
Measurement Instruments (COSMIN) checklist (16). The full process and results are 
described elsewhere (14). Each PROM was appraised for three main and eight subcategories, 
namely reliability (subcategories: internal consistency, test-retest reliability, measurement 
error), content validity (subcategories: content validity, structural validity, hypothesis testing, 
cross cultural validity, criterion validity), and responsiveness (16).  
In addition, new and potential instruments that measure physical function were 





3. Discussion and Delphi exercise to achieve concensus regarding instrument prioritization 
A comprehensive document on the physical function PROMs was developed and 
presented to working group members (Supplementary document). This included the 
background of the PROMs, format and scoring methods. Included in the document was a 
Summary of Measurement Properties Table that detailed the measurement properties of the 
PROMs appraised in the previous work (14). A teleconference was conducted among 
working group members to discuss the various PROMs and the Delphi format. The working 
group decided on having two rounds of Delphi exercises, with interim discussions via 
teleconference or email to facilitate achieving consensus on prioritizing physical function 
PROMs. All Delphi exercises were conducted anonymously on online portals. 
In the first Delphi exercise, working group members were asked to vote based on their 
own understanding of the PROMs. Working group members were advised to focus primarily 
on whether the PROMs matched to the domain of physical function in PsA and on the 
feasibility of the PROMs. Working group members were also given the Summary of 
Measurement Properties Table derived from the previous published work (14). However, this 
information was considered secondary, as the full set of evidence required by  OMERACT 
Filter 2.1 had not been developed. In particular, RCT evidence for discrimination was not 
included. A question for each PROM was asked, “Do you think this PROM should be taken 
forward for further evaluation?”. A simple yes/no response for each PROM was requested, 
and additional comments were collected as free text. 
The results of the voting of the first Delphi exercise were discussed. The working 
group then drafted the questions for a second Delphi exercise. In the second Delphi exercise, 
it was prespecified that PROMs receiving ≥70% endorsement would be included for further 








1. Formation of the physical function working group 
A physical function working group of 13 members was formed in June 2018. The 
final members of the working group consisted of experts (10 rheumatologists and one 
methodologist) with experience in physical function measurement in PsA, and two PRPs. 
Working group members had international representation, spanning across three continents 
(countries of origin: Australia, Canada, Denmark, Hong Kong SAR of China, Singapore, UK, 
and USA). Two teleconference sessions with additional PRPs were conducted to explain the 
purpose of study, work flow, instruments for consideration of assessment of physical function 
domain and the OMERACT Filter 2.1 methodology.  
 
2. Identification of PROMs for physical function 
Physical function in PsA was defined as “Being able to perform physical activities 
from daily to recreational activities (includes upper/lower extremity functioning, balance)”  
(17). Examples of the concept of physical function were taken from quotations from a 
GRAPPA international focus group study (9) and summarized in Table 1 of the 
Supplementary document. Based on this definition and the concept of physical function being 
the perception of physical capability, the working group therefore decided to focus on 
PROMs instead of performance-based assessments.  
We identified relevant physical function PROMs from a recent comprehensive SLR 
on PROMs for various domains in PsA (14). The evidence derived from the SLR for physical 
function PROMs was extracted from the published article (14) and presented to working 
group members for review and discussion (Supplementary document). These PROMs were: 





(HAQ-S) (19), modified HAQ (mHAQ) (20), Physical Functioning domain of the Medical 
Outcomes Study 36-item Short Form Survey (SF-36 PF10) (21), Physical Component 
Summary Score of the SF-36 (SF-36 PCS) (21), PCS of the SF-12 (SF-12 PCS) (22), 
Psoriatic Arthritis Impact of Disease (PsAID) functional capacity item (23), Arthritis Impact 
Measurement Scales (AIMS) (24), Bath Ankylosing Spondylitis Functional Index (BASFI) 
(25), and the American College of Rheumatic Diseases (ACR) functional class (26). Two 
additional PROMs were suggested by working group members: multidimensional HAQ 
(MDHAQ) (27) and the Patient-Reported Outcomes Measurement Information System 
(PROMIS)-Short Form Physical Function 10a (PROMIS-PF10a) (28). The MDHAQ has 
been incorporated in the Routine Assessment of Patient Index Data 3 (RAPID3) that was 
developed for use in clinical care in RA (29), and is being incorporated as a routine 
measurement in clinical care for PsA in some countries. The PROMIS-PF10a was developed 
based on item banks for physical function. 
Relevant information for these 12 physical function PROMs was summarized in a 
comprehensive document and circulated to all working group members (Supplementary 
document). The document listed all the 12 PROMs with a short introduction and scoring 
methods. A Summary of Measurement Properties table taken from the previous SLR of 
PROMs was enclosed. Working group members were asked to review the information and 
prepare for the Delphi exercise. 
 
3. Working group discussions and Delphi exercises 
The first Delphi exercise was conducted in June 2018 and finalized on 12 July 2018 
via an anonymized online voting portal. All 13 working group members participated 
(response rate 100%). The voting results of the first Delphi exercise and comments made to 





The results of the first Delphi exercise were then presented to the working group 
members, followed by open discussion via email from 12 - 27 July 2018. A one-hour web-
based discussion was conducted on 23 August 2018, followed by further open discussion via 
email from 23 August to 19 September 2018. During the teleconferences and subsequent 
e-mail communications, members of the working group were allowed to speak freely on their 
views of the PROMs. Based on the discussion points, a script for a second Delphi exercise 
was drafted and reviewed by all working group members. Several revisions of the phrasing 
and wording were done and finally agreed upon by all members of the working group (Table 
2).  
In the second round of the Delphi exercise, results of the overall voting of the working 
group in the first round of Delphi exercise and discussion points were made available. Again, 
working group members were asked whether or not to take the individual PROM to appraisal 
via OMERACT Filter 2.1, based on their understanding of domain match, feasibility and 
measurement properties. It was prespecified that instruments receiving <70% endorsement in 
the second Delphi exercise would be excluded from further formal appraisal. All 13 working 
group members participated in the second Delphi exercise and results with reasons for the 
inclusion or exclusion of all PROMs are summarized in Table 2.  
The HAQ and modifications.  The HAQ-DI was originally developed for RA and adapted for 
arthritis in general (18). It includes 20 items assessing eight aspects of physical function: 
dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. As the 
most commonly used instrument to assess physical function in PsA RCTs (12), it received 
unanimous endorsement in both Delphi exercises.  
The HAQ-S, a modification of the original HAQ-DI with 5 additional items assessing 





data have demonstrated that the HAQ-S does not capture additional information compared 
with HAQ-DI (30), some members thought that this result may have been related to the 
original PsA cohort in which the HAQ-S was tested and needed further testing in populations 
enriched for the presence of axial PsA. Both HAQ-DI and HAQ-S have been collected in the 
large Corrona registry in the United States, thus there is a potential that comparative data 
about performance of the two instruments in patients whose PsA includes axial involvement 
will become available from the registry. In the second Delphi exercise, use of the HAQ-S was 
addressed with two questions: the first was whether or not to include, and the second was to 
allow use of either the HAQ-DI or HAQ-S dependent on the clinical setting. With these 
considerations, the HAQ-S received 79% and 84% of the votes in favor of inclusion.   
The mHAQ is a shortened version of HAQ-DI with only 8 items, one from each 
subdomain of the HAQ-DI (20); it received >70% of the votes for inclusion in both Delphi 
exercises. The MDHAQ, which includes the 8 items of mHAQ with 2 additional items 
(patient global assessment of disease activity and pain) (27), was presented as part of the 
RAPID3 in the first Delphi when it received only 69% of the votes. During the teleconference 
discussion, the 10-item MDHAQ was clarified as an instrument purely to assess physical 
function. Consensus was achieved to retain the MDHAQ in the second Delphi exercise, with 
a vote of 76% to be included. 
The Medical Outcomes Study Surveys.  The SF-36 PCS received 61.5% of the vote in the first 
Delphi. Although the results of SF-36 PCS scores have been reported in many RCTs, there 
were concerns expressed by the working group regarding the concept represented by the 
summary scores of the SF-36, as they are calculated based on positive and negative weighting 
of all 8 domains with a population norm of a mean (standard deviation) of 50 (10). The key 
utility of this norm-based scoring is for easy comparison of the summary scores at a group 





SF-36 PCS represents a broader concept than physical function alone (21, 31), and therefore 
not having the domain match. The SF-36 PCS was excluded following the second Delphi 
exercise. In contrast, the PF domain of the SF-36 (SF-36 PF10) that includes 10 items 
measuring physical function matched with the domain intended to measure. The SF-36 PF10  
received unanimous endorsement for inclusion from both Delphi exercises. It has been noted, 
however, that to use the SF-36 PF10, the entire SF-36 HRQoL questionnaire must be scored 
(21, 31). 
Based on the same reasoning by which the SF-36 PCS was excluded, the working 
group felt the SF-12 PCS did not represent the physical function domain (lack of domain 
match), and there is no existing study that has evaluated its exclusive use in PsA. The SF-12 
PCS was excluded from the second round of the Delphi exercise and further consideration. 
The PsAID functional capacity item.  PsAID is a PsA-specific derived multidimensional 
instrument that measures the life impact of PsA. It is often considered a HRQoL measure (23). 
Physical function is represented by a single item with an 11-point numeric rating scale (0-10) 
as functional capacity impact attributed to PsA.  It received 84.6% of the votes in the first 
Delphi. Concerns were raised regarding the validity of utilizing a single item from a 
composite measure of HRQoL, and the domain match of the item itself. Consensus excluded 
the PsAID functional capacity item from further evaluation in the second Delphi exercise. 
PROMIS-PF10a.   Despite the lack of validation data, the working group thought that the 
PROMIS-PF10a could be a promising instrument. The PROMIS-PF10a was developed from 
a 1,728-item bank taken from 165 instruments assessing physical function. It received 92.3% 
and 100% of the votes for inclusion in the first and second Delphi exercises, respectively. 
Other PROMs. The AIMS, BASFI and ACR functional class received 30.8%, 61.5% and 





long, thereby lacking feasibility, and it has not been used in the last decade. The BASFI was 
considered not to have adequate domain match as well as not providing additional 
information beyond the HAQ-DI. The ACR functional class was considered to be lacking 
domain match as it is too crude an instrument for measuring physical function in PsA patients 
who currently are less physically impaired or disabled following the new treatment strategies 
(32).  These three instruments were considered as a single question in the second Delphi 




In this report we summarize the process leading to a preliminary prioritization of 
PROMs for assessment of physical function in PsA RCTs and LOS. Six PROMs for 
assessment of the physical function domain in PsA were successfully prioritized for further 
appraisal: HAQ-DI, HAQ-S, mHAQ, MDHAQ, SF-36 PF10, and PROMIS-PF10a. These 
prioritized PROMs will undergo formal appraisal of specific measurement properties using 
the OMERACT Filter 2.1 individually.   
Members of GRAPPA are committed to standardizing the core outcome measurement 
set in PsA RCTs and LOS which is essential to minimize heterogeneity and facilitate 
interpretation of the studies (7). With updating of the PsA Core Outcome Set, research 
processes have been underway to evaluate instruments for each of the specified domains. We 
tested a consensus-based process for candidate instrument triage and showed its feasibility to 
prioritize instruments for the physical function domain. This process as illustrated in Figure 1 
was drafted following a consensus effort from the steering committee including input from 





instruments with high potential for fulfilling the OMERACT Filter 2.1 for instrument 
selection. Its application may be especially useful when assessing domains that have 
numerous existing measurement instruments developed over the years, often for other 
indications, particularly for domains such as physical function and HRQoL.  This template 
may be less useful for highly specific PsA domains such as enthesitis where few instruments 
are specifically developed and available, so that the working group may not need a method to 
shortlist instruments.  
The work processes in this template (Figure 1) consisted of forming a working group 
with representative stakeholders, identification of PROMs through SLR, thorough 
discussions on content and feasibility of the instruments, and achievement of consensus 
through Delphi exercises. This template provided a platform for the working group to exclude 
instruments that have inadequate domain match, poor feasibility or otherwise low potential 
from further formal appraisal using the OMERACT Filter 2.1. It also allowed new 
instruments that have less established evidence but high potential to be considered for further 
evaluation.  
The strengths of this current report include collaborative work from health care 
professionals and PRPs to prioritize instruments for further appraisal. The working group 
members have expertise in the physical function domain in PsA with international 
representation. There are some limitations in interpretation that require highlighting. The 
consensus Delphi exercises were conducted among the 13 working group members rather 
than involving a larger number of stakeholders, recognizing that the discussions among the 
stakeholders were deep and thorough. During the Delphi exercises, working group members 
voted for the PROMs based on their overall impression of the PROMs. These gaps will be 
bridged eventually as each of the prioritized PROMs will be taken forward to formal 





standized outcome measurement set will be presented instrument by instrument, and 
endorsement from a larger GRAPPA and OMERACT community will be sought.  
In summary, we report application of consensus-driven template to prioritize multiple 
instruments for further appraisal for the physical function domain in PsA, in a project to 
standardize the Core Outcome Set in PsA.  We prioritized 6 PROMs for use in RCTs and 
LOS via a concerted effort from experts and PRPs.  These prioritized physical function 











Table 1. Comments from the working group given for each physical function PROM. 
PROMs First Delphi 
exercise voting 
results 
N (%) for “Yes” 
For   Against  
HAQ-DI 13 (100) • It has been used in most LOS and RCTs in PsA 
• Most of the measurement properties have been 
appraised 
• Nil 
HAQ-S 9 (69.2) • The additional item addressed physical 
impairment related to cervical spine involvement 
in PsA. 
• One paper suggested that HAQ-S and HAQ-DI 
provided similar information. It is possible that 
there was an inadequate number of patients of 
each subtype to show the differences, or patients 
included were not reflective of the full spectrum 
of axial involvement.  
• It has been incorporated in the Corrona registry 
with a larger proportion of PsA patients with 
axial involvement. Further data analysis may 
provide an answer to whether it adds new 
information. 
• The additional items (eg, working at a desk, 
driving a car) are too specific and not relevant 
for all patients. 
• It provides no additional information compared 
to the HAQ-DI.  
mHAQ 10 (76.9) • It is a shorter version of HAQ-DI. 
• It has been incorporated in the Corrona registry 
with a larger proportion of PsA patients with 
axial involvement. Further data analysis may 
provide an answer to whether it adds new 
information. 
• It may be too brief. 
• It provides the same information as the 
HAQ-DI. 
• There are currently minimal data on its 
measurement properties 
RAPID3 9 (69.2) • The first 10 items of RAPID3 are actually the 
MDHAQ, which can be calculated as a Physical 
• RAPID3 measures HRQoL. It does not entirely 





Function score. • Items 1-10 describe physical function, while the 
rest were pain, patient global assessment and 
psychological impact. It is not clear if it 
measure disease activity or impact. 
• The score categories are confusing (eg, near 
remission, low severity).  
SF-PF10 13 (100) • The SF-36 has been used in most RCTs for PsA, 
for which SF-PF10 can be derived. 
• Nil 
SF-36 PCS 8 (61.5) • The SF-36 has been used in most RCTs for PsA, 
and the SF-36 PCS results have been reported in 
many RCTs. 
• The SF-36 PCS is not a measure of physical 
function; it is calculated based on all 8 domains 
using a very complicated equation. It measures 
many concepts in addition to physical function. 
It is used to determine statistical significance so 
that the individual domains may be interrogated 
without a p value correction. 
• The SF-36 PCS does not match the domain of 
physical function. It is a measure of HRQoL 
(includes all 8 weighted domains of the SF-36 
questionnaire).  
SF-12 PCS 5 (38.5) • The SF-12 is a shorter version of the SF-36, 
which may be more feasible than the SF-36. 
• Similar to the SF-36, the SF-12 PCS does not 
match to the domain of physical function, but a 
measurement of HRQoL. 
• There are no data for use of SF-12 PCS in PsA.  
• The SF-12 PCS was not listed in the previous 




12 (92.3) • The PROMIS-PF10a was derived from a huge 
item bank, and may have higher precision in 
measurement of physical function. 
• The measurement properties of PROMIS-
PF10a have not been evaluated in PsA. 









11 (84.6) • The PsAID has received provisional endorsement 
from OMERACT as a measure of HRQoL in 
PsA. 
• The PsAID should be taken as a whole for the 
measurement of HRQoL in PsA, rather than 
broken down into components. 
• It is an 11-point numeric rating scale for 
physical function. There is lack of granularity 
as a single item to measure a domain. The 
precision is expected to be low.  
AIMS 4 (30.8) • It seems to be thorough and have good domain 
match with the qualitative description (arm 
function, mobility, walking and bending, hand 
and finger). 
• It is too long to be feasible. 
• It has not been used for many years.  
• Patients’ previous feedback with AIMS was 
negative. It would be difficult to persuade 
patients to complete PROMs they do not like. 
• There are only limited data available on 
measurement properties. 
BASFI 8 (61.5) • It has relevant items for axial function including 
the cervical spine. 
• It is not meant to measure physical function in 
PsA. There is a lack of content validity in 
measuring physical function in PsA. 
• The content does not represent concerns in PsA 
patients with axial involvement. It is not 
specific to PsA patients with axial involvement. 
• It has too much focus on axial function. 
• It has poor psychometric properties in PsA. 




4 (30.8) • While developed for RA, it has some broadly 
generalizable information usable in clinical trials, 
such as that for inclusion or exclusion criteria.  
• It is too brief. 
• It is an outdated instrument that is not in use. 
• It may lack content for PsA patients nowadays 
where severe disabling is seldomly seen. 
• The level of response and categories are 
difficult to understand. 





physical function from patients’ perspective. 
• It is too crude, only having a few levels of 
responses that span across fully functional to 
bedridden. 
• Given the crude categories, the responsiveness 
is expected to be poor. 
 
Abbreviations: ACR, American College of Rheumatology; AIMS, Arthritis Impact Measurement Scales; BASFI, Bath Ankylosing Spondylitis Functional index; HAQ, 
Health Assessment Questionnaire (HAQ-S: Spondyloarthropathy, HAQ-DI: Disability Index); mHAQ; modified HAQ; MDHAQ, multidimensional HAQ; SF-36, Medical 
Outcomes Study 36-item Short Form Survey (PCS: Physical Component Summary; PF: SF-36 physical functioning domain); PsAID, Psoriatic Arthritis Impact of Disease; 

















N (%) for “Yes” 
[final decision] 
HAQ-DI 13 (100) • HAQ-DI received 100% votes in the first Delphi. 
 





HAQ-S 9 (69.2) • HAQ-S has 5 additional items for spine added to HAQ-DI. It was previously 
shown to give similar information as HAQ-DI. However, it may be relevant 
for patients with axial PsA. It has been incorporated in the Corrona registry 
with data pending.  
• HAQ-S received 69.2% votes in first Delphi. 
 
• Given this consideration, should we appraise HAQ-S via OMERACT Filter 
2.1? 





 • Secondly, are you agreeable to see HAQ-DI and HAQ-S as a family. If 
evidence is supportive of HAQ-S as useful for axial PsA, to allow using 




mHAQ 10 (76.9) • mHAQ is a shorter version of HAQ-DI (8-items) 
• It received 76.9% votes in the first Delphi. 
 








MDHAQ Voted under 
RAPID3 
9 (69.2) 
• MDHAQ is modified from HAQ. It consists of a 10-item physical function 
score, pain, stiffness, fatigue, and patient global.  
• Rated under RAPID3 (which consisted of the 10-item physical function, 
pain and patient global), it received a 69.2% vote in the first Delphi.  
• The 10-item physical function of MDHAQ is purely for physical function 
and can be taken as independent scale. 
 
• Do you think we should appraise the physical function score of MDHAQ via 




SF-36 PF10 13 (100) • SF-PF10 has received a 100% vote in the first Delphi. 
 





SF-36 PCS 8 (61.5) • SF-36 PCS has been reported in clinical trials. 
• However, it is not measuring the domain of physical function. 
• It received a 61.5% vote in the first Delphi. 
 





SF-12 PCS 5 (38.5) • SF-12 PCS was not in the systematic review. There is no study that 





12 (92.3) • PROMIS-PF10a (short form) has only 10 items.  
• It is a promising generic measure of physical function 
• It received a 92.3% vote in the first Delphi 
 









PsAID item 5 
functional 
capacity 
11 (84.6) • PsAID item #5 functional capacity received 84.6% votes in the first Delphi. 
• Discussion has been not to select individual items from an instrument, single 
items do not measure a domain well, there has been no validation of the 
PsAID item #5 as a stand-alone measure of physical function, and PsAID12 
as a whole does not match the physical function domain. 
• It may be relevant to see if #5 functional capacity is consistent with other 
physical function measures. 
 
• Given this consideration, should PsAID #5 functional capacity be appraised 




AIMS 4 (30.8) • AIMS is a long instrument and lacks feasibility. It has not been used in the 
community. It has received only 30.8% vote in the first Delphi. 
• Discussion around BASFI has been on lack of domain match, even for axial 
PsA; and giving similar information as HAQ-DI or HAQ-S. It received a 
61.5% vote in the first Delphi. 
• Discussion on ACR functional class has been that it is too crude, lacks 
domain match with lesser physical impairments among patients nowadays, 
and is not used much in the field. It has received only 30.8% vote in the first 
Delphi. 
 
• Given the above considerations, should AIMS, BASFI and ACR functional 
class be appraised via OMERACT Filter 2.1? 
Yes/ No 
0 (0) 




Response rate from 13 working group members 100%. 
Abbreviations: ACR, American College of Rheumatology; AIMS, Arthritis Impact Measurement Scales; BASFI, Bath Ankylosing Spondylitis Functional index; HAQ, 
Health Assessment Questionnaire (HAQ-S: Spondyloarthropathy, HAQ-DI: Disability Index); mHAQ; modified HAQ; MDHAQ, multidimensional HAQ; SF-36, Medical 
Outcome Survey Short Form 36-item Health Survey (PCS: Physical Component Summary; PF: SF-36 physical function subscale); PsAID, Psoriatic Arthritis Impact of 






Supplementary Table 1. Examples of quotations of Physical Function taken from the 
International focus group study by GRAPPA 
❖ What affects me the most is not being able to do certain things because we get 
immobilized. I can't bend down, I can't lift my arm much, because it hurts, so there are 
certain things you can't do. (Brazil)  
 
❖ [The walking cane] helps me to walk and most importantly it helps me keep my 
balance. It didn't really change my relationship with the people around me. It is to help 
me, because my ankle, my knee, my hip, suddenly... I lose control. I recover by using 
my cane, still suffering, as my hands are also painful. (France) 
 
❖ It is hard to move or lift objects and once in a while it is even hard to wake up and get 
perpendicular. There are days that waking up and getting up is really difficult, even 
turning around in bed can be difficult. (France) 
 
❖ -Sometimes I cannot even peel potatoes, well then I'm working with an electric potato 
peeler (laughs)-That goes electrically because then you cannot hold it.-Yes the 
housekeeping is pretty restrictive. (exchange between participants, Netherlands)  
 
❖ I’m just so stiff. It’s hard to straighten by body out and get my legs under me and 
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